Literature DB >> 10972674

Inhibition of heparin-binding epidermal growth factor-like growth factor increases albuminuria in puromycin aminonucleoside nephrosis.

T F Khong1, S Fraser, M Katerelos, K Paizis, P A Hill, D A Power.   

Abstract

BACKGROUND: Our previous work in the acute puromycin aminonucleoside nephrosis (PAN) model has demonstrated up-regulation of heparin-binding epidermal growth factor-like growth factor (HB-EGF) mRNA and protein within glomerular epithelial cells (GECs) prior to the onset of proteinuria.
METHODS: To determine whether increased HB-EGF expression in the acute PAN model contributes to the pathogenesis of proteinuria, a monoclonal antibody (DE10) was produced against recombinant human HB-EGF.
RESULTS: The specificity of DE10 for human HB-EGF was confirmed by enzyme-linked immunosorbent assay, immunohistochemical staining, and flow cytometry of transfected cells expressing human and rat HB-EGF, and inhibition of cell proliferation. DE10 also reacted with cells transfected with rat HB-EGF cDNA. Administration of 0.5 mg affinity-purified DE10 to normal rats did not cause significant albuminuria compared with controls. Five days after the induction of the acute PAN model, albuminuria was significantly greater in animals treated with 0.5 mg DE10 than a control mAb (162.6 +/- 32.4 vs. 64.8 +/- 10.2 mg/day, respectively, P < 0.01). Rats treated with DE10 had an earlier onset of severe albuminuria, but no increase in maximal albuminuria at later time points. Electron microscopy showed marked podocyte effacement in both DE10-treated and control animals, but no obvious difference between groups. However, adhesion of the human GEC line 56/10 A1 to laminin and fibronectin, but not to collagens I or IV, was reduced by DE10.
CONCLUSIONS: This study suggests that HB-EGF contributes to the integrity of the glomerular filtration barrier, particularly when the podocyte has been injured. Following podocyte injury, adhesion to laminin in the glomerular basement membrane by HB-EGF may be important in reducing albuminuria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10972674     DOI: 10.1046/j.1523-1755.2000.00267.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

Review 1.  Epidermal growth factor receptor mediates injury in rapidly progressive glomerular disease.

Authors:  Sabine Brandt; Peter R Mertens
Journal:  Int Urol Nephrol       Date:  2012-03-24       Impact factor: 2.370

2.  Characterization of a variety of neutralizing anti-heparin-binding epidermal growth factor-like growth factor monoclonal antibodies by different immunization methods.

Authors:  Isamu Tsuji; Shuji Sato; Kentaro Otake; Takahiro Watanabe; Hiroko Kamada; Tomofumi Kurokawa
Journal:  MAbs       Date:  2012-09-24       Impact factor: 5.857

Review 3.  The epidermal growth factor receptor pathway in chronic kidney diseases.

Authors:  Laura R Harskamp; Ron T Gansevoort; Harry van Goor; Esther Meijer
Journal:  Nat Rev Nephrol       Date:  2016-07-04       Impact factor: 28.314

4.  Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis.

Authors:  Guillaume Bollée; Martin Flamant; Sandra Schordan; Cécile Fligny; Elisabeth Rumpel; Marine Milon; Eric Schordan; Nathalie Sabaa; Sophie Vandermeersch; Ariane Galaup; Anita Rodenas; Ibrahim Casal; Susan W Sunnarborg; David J Salant; Jeffrey B Kopp; David W Threadgill; Susan E Quaggin; Jean-Claude Dussaule; Stéphane Germain; Laurent Mesnard; Karlhans Endlich; Claude Boucheix; Xavier Belenfant; Patrice Callard; Nicole Endlich; Pierre-Louis Tharaux
Journal:  Nat Med       Date:  2011-09-25       Impact factor: 53.440

5.  A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.

Authors:  Shuji Sato; Andrew W Drake; Isamu Tsuji; Jinhong Fan
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

6.  Erlotinib preserves renal function and prevents salt retention in doxorubicin treated nephrotic rats.

Authors:  Raed N Bou Matar; Janet D Klein; Jeff M Sands
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.